KawaguchiY., KawanishiH., MujaisS., TopleyN., OreopoulosD.G.Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis.Perit Dial Int2000; 20(Suppl 4): S43–55.
2.
MachadoD.J., CocuzzaC.S., NahasW.C., IanhezL.E.Sclerosing encapsulating peritonitis after renal transplantation. Does it make sense?Perit Dial Int2000; 20: 341–3.
3.
De FrietasD., HurstH., JordaanA., TavakoliA., BrenchleyP., HutchisonA.Encapsulating peritoneal sclerosis (EPS) following renal transplantation [Abstract].Perit Dial Int2006; 26(Suppl 2): S116.
4.
KorteM.R., YoM., BetjesM.G., FierenM.W., van SaaseJ.C., BoerW.H.Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation.Nephrol Dial Transplant2007; 22: 2412–14.
5.
FierenM.W., BetjesM.G., KorteM.R., BoerW.H.Posttransplant encapsulating peritoneal sclerosis: a worrying new trend?Perit Dial Int2007; 27: 619–24.
6.
RigbyR.J., HawleyC.M.Sclerosing peritonitis: the experience in Australia.Nephrol Dial Transplant1998; 13: 154–9.
7.
KhannaA., PlummerM., BromberekC., BresnahanB., HariharanS.Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity.Kidney Int2002; 62: 2257–63.
8.
ShihabF.S., BennettW.M., TannerA.M., AndohT.F.Mechanism of fibrosis in experimental tacrolimus nephrotoxicity.Transplantation1997; 64: 1829–37.
9.
DumanS., BozkurtD., SipahiS., SezakM., OzkanS., ErtilavM.Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model.Adv Perit Dial2008; 24: 104–10.
10.
van WestrhenenR., AtenJ., HajjiN., de BoerO.J., KunneC., de WaartD.R.Cyclosporin A induces peritoneal fibrosis and angiogenesis during chronic peritoneal exposure to a glucose-based, lactate-buffered dialysis solution in the rat.Blood Purif2007; 25: 466–72.
11.
DejagereT., EvenepoelP., ClaesK., KuypersD., MaesB., VanrenterghemY.Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient.Am J Kidney Dis2005; 45: e33–7.
12.
GrinyoJ.M., CruzadoJ.M.Mycophenolate mofetil and sirolimus combination in renal transplantation.Am J Transplant2006; 6: 1991–9.
13.
DeanP.G., LundW.J., LarsonT.S., PrietoM., NybergS.L., IshitaniM.B.Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus.Transplantation2004; 77: 1555–61.
14.
SchenaF.P., PascoeM.D., AlberuJ., del Carmen RialM., OberbauerR., BrennanD.C.Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month safety and efficacy results from the CONVERT Trial.Transplantation2009; 87: 233–42.
15.
SekiguchiY., PattersonS., LiuL., MargettsP.J.Inhibition of mammalian target of rapamycin (mTOR) in peritoneal fibrosis [Abstract].Perit Dial Int2009; 29(Suppl 4): S17.
16.
RajaniR., SmythJ., KoffmanC.G., AbbsI., GoldsmithD.J.Differential effect of sirolimus vs prednisolone in the treatment of sclerosing encapsulating peritonitis.Nephrol Dial Transplant2002; 17: 2278–80.
